Konstantinos N Aronis1, Ayse Sahin-Efe2, John P Chamberland2, Avron Spiro3, Pantel Vokonas4, Christos S Mantzoros5. 1. Section of Endocrinology, VA Boston Healthcare System, Harvard Medical School; Division of Endocrinology Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School; Department of Medicine, Boston Medical Center, Boston University School of Medicine. Electronic address: konstantinos.aronis@bmc.org. 2. Section of Endocrinology, VA Boston Healthcare System, Harvard Medical School; Division of Endocrinology Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School. 3. Normative Aging Study, VA Boston Healthcare System and Boston University Schools of Public Health and Medicine. 4. Normative Aging Study, VA Boston Healthcare System and Boston University School of Medicine. 5. Section of Endocrinology, VA Boston Healthcare System, Harvard Medical School; Division of Endocrinology Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School; Department of Medicine, Boston Medical Center, Boston University School of Medicine.
Abstract
OBJECTIVE: Chemerin is a recently identified adipocytokine that has been positively correlated with the presence and severity of coronary artery disease (CAD). However, no studies have examined circulating chemerin levels as a predictor of acute coronary syndrome (ACS). The purpose of this study is to evaluate whether chemerin levels predict the onset of ACS. MATERIALS/ METHODS: We studied 90 men whose serum had been collected at least 2 years before the development of ACS, and 162 controls matched with the cases in a 1:2 fashion for age and year of collection. The mean age of the cohort was 66.3±9.6 years (range 34-84 years). Serum chemerin levels were measured with a commercially available enzyme-linked immunosorbent assay. RESULTS: Age was positively associated with chemerin levels (r=0.39, p<0.001). Logistic regression analysis, adjusting for years since blood collection, demonstrated a null association between chemerin levels and the odds ratio for development of ACS (OR: 0.99, 95% CI [0.99-1.001]). This association remained null after adjusting for age (OR: 0.99 95% CI [0.99-1.001]). CONCLUSIONS: Although cross-sectional and case-control studies suggest a positive association between chemerin levels and CAD, we demonstrate that chemerin levels do not predict the development of ACS.
OBJECTIVE:Chemerin is a recently identified adipocytokine that has been positively correlated with the presence and severity of coronary artery disease (CAD). However, no studies have examined circulating chemerin levels as a predictor of acute coronary syndrome (ACS). The purpose of this study is to evaluate whether chemerin levels predict the onset of ACS. MATERIALS/ METHODS: We studied 90 men whose serum had been collected at least 2 years before the development of ACS, and 162 controls matched with the cases in a 1:2 fashion for age and year of collection. The mean age of the cohort was 66.3±9.6 years (range 34-84 years). Serum chemerin levels were measured with a commercially available enzyme-linked immunosorbent assay. RESULTS: Age was positively associated with chemerin levels (r=0.39, p<0.001). Logistic regression analysis, adjusting for years since blood collection, demonstrated a null association between chemerin levels and the odds ratio for development of ACS (OR: 0.99, 95% CI [0.99-1.001]). This association remained null after adjusting for age (OR: 0.99 95% CI [0.99-1.001]). CONCLUSIONS: Although cross-sectional and case-control studies suggest a positive association between chemerin levels and CAD, we demonstrate that chemerin levels do not predict the development of ACS.